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Background: Tumour microenvironment is a fundamental aspect of tumour behaviour, modulating important
events as cancer cell migration and invasion, as well as angiogenesis and metastisation. Among other
microenvironment features, hypoxia and acidity play important roles in this modulation. As the metabolic
reprogramming of cancer cells induces extracellular acidity, which in turn induces angiogenesis, and hypoxia
induces both the metabolic reprogramming and angiogenesis, the present study aims to evaluate the
immunohistochemical expression of a variety of metabolic and vascular markers as common targets of the hypoxic
microenvironment in a series of cervical squamous cells carcinoma, as well as using an in vitro 3D culture model.
Methods: Immunohistochemical expression of MCT1, MCT4, CD147, GLUT1 and CAIX was assessed in a series of 28
chronic cervicitis, 34 LSIL, 29 HSIL, 38 cases of squamous cells carcinoma (SCC), as well as in in vitro 3D culture of
keratinocytes expressing HPV genes. Furthermore, VEGF family members’ expression was assessed in the SCC cases.
The expression profiles were associated with patients’ clinicopathological parameters.
Results: We found an increase of MCT4 expression along progression to malignancy in cervical samples. Also,
MCT4 was associated with CD147 and CAIX expression. VEGF-A expression was more frequently found in cases
without MCT1 expression. Both MCT4 and CD147 were more frequently expressed in younger patients at diagnosis
while no associations were found between VEGF family and clinicopathological parameters. Finally, we show
evidence for the upregulation of MCT4, as well as CD147 and CAIX, after HPV transfection.
Conclusions: The results herein presented point at MCT4 as a promising therapeutic target in squamous cells
carcinoma of the uterine cervix. Importantly, we show a possible association between lactate transport and
angiogenesis, which should be further explored.
Keywords: Angiogenesis, Cervical carcinoma, Hypoxia, Lymphangiogenesis, Metabolic reprogramming,
Monocarboxylate transporter, VEGF* Correspondence: longatto16@hotmail.com
1Life and Health Sciences Research Institute (ICVS), School of Health Sciences,
University of Minho, Braga, Portugal
2ICVS/3B’s - PT Government Associate Laboratory, Braga/Guimarães, Portugal
Full list of author information is available at the end of the article
© 2014 Pinheiro et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Pinheiro et al. BMC Cancer 2014, 14:751 Page 2 of 12
http://www.biomedcentral.com/1471-2407/14/751Background
Monocarboxylate transporters (MCTs) are a family of 14
members and isoforms 1–4 are responsible for the co-
transport of monocarboxylates with a proton [1]. They
are of extreme importance in the cancer context since
they perform a key dual role in the metabolic homeosta-
sis of cancer cells. It is widely known that cancer cells
rely on the conversion of glucose into lactate, even in
the presence of oxygen, for energy and anabolic interme-
diates production, a phenomenon known as the Warburg
effect [2]. In this context, MCTs, especially MCT1 and
MCT4, are crucial for the cellular export of the high
amounts of lactate resultant from the high glycolytic ac-
tivity. Besides, they are also important contributors for
intracellular pH maintenance, by partially exporting the
protons resultant from the metabolic activity, therefore
avoiding intracellular acidification and, consequently, cell
death. Importantly, both MCT1 and MCT4 require
CD147 as an ancillary protein for correct plasma mem-
brane location and activity [3].
Hypoxia has become a central subject in tumour phy-
siology and cancer treatment. It is primarily a patho-
physiologic consequence of oxygen diffusion limitations,
due to exacerbated cell proliferation as well as inade-
quate and chaotic angiogenesis [4]; however, evidence
from experimental and clinical studies point to a funda-
mental role of hypoxia in tumour dissemination, pro-
gression and resistance to therapy [5]. In cervical cancer,
hypoxia was shown to be associated with shorter 5-year
survival for FIGO stage III patients [6]. Importantly,
hypoxia, through the transcription factor hypoxia indu-
cible factor 1 alpha (HIF-1α), is the major regulator of
cancer cell metabolism, stimulating the Warburg effect
[7]. Actually, glucose transporter 1 (GLUT1) and car-
bonic anhydrase IX (CAIX), which are important players
in the hyper-glycolytic and acid-resistant phenotype of
cancer cells, are HIF-1α targets [8,9]. Other important
targets of HIF-1α regulation include MCT4 and vascular
endothelial growth factor (VEGF) [10].
The VEGF family is formed by a group of highly con-
served factors regulating vasculogenesis, haematopoiesis,
angiogenesis, lymphangiogenesis and vascular permea-
bility [11], and some of the members are thus considered
important therapeutic targets [12,13]. In mammals, the
family comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D
and placental growth factor (PlGF). VEGF-A is primarily
related to angiogenesis while VEGF-C and VEGF-D are
involved in lymphangiogenesis [14]. Little is known about
the meaning of VEGF-B expression in tumours [11]. The
family also include three tyrosine kinase receptors (TKR):
VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR-3 (Flt-4).
The VEGFR-1 (vascular endothelial growth factor re-
ceptor 1) binds to VEGF-A and -B, VEGFR-2 binds to
VEGF-A, −C and -D and VEGFR-3 binds to VEGF-Cand -D [15]. The increased expression of VEGF family
in tumours has been associated with poor prognosis or in-
creased risk of recurrence or metastasis in several types of
cancers [16] and, currently, several pro- or anti-angiogenic
drugs have been approved by the FDA or are in clinical
trials [17]. Very recently, in advanced cervical cancer, the
use of the humanized anti-VEGF monoclonal antibody
bevacizumab, in combination with chemotherapy, showed
and improvement in patients’ overall survival [18]. Im-
portantly, the Warburg effect may contribute to vascular
modulation as tumour acidity facilitates angiogenesis [19]
and lactate, also a contributor of tumour acidity, may itself
induce VEGF [20].
Cervical cancer is still highly prevalent in developing
and poor countries and studies on the biology related to
the carcinogenesis associated with the high risk HPV in-
fection is critical to understand the behaviour of these
tumours and propose alternatives for their therapy and
control [21].
Therefore, the present study was designed to evaluate
the immunohistochemical expression of a variety of me-
tabolic and vascular markers as common targets of the
hypoxic microenvironment, assess the associations bet-
ween them and associate their expression with the clinical
and pathological behaviour of squamous cell carcinomas
of the uterine cervix. Additionally, we also characterized
the expression of the metabolic markers in in vitro 3D cul-
ture of keratinocytes transduced with HPV16 oncogenes
or transfected with HPV16 or HPV18 full-length genome.
Methods
Human uterine cervix samples
The human biological samples analysed included 129
formalin-fixed paraffin embedded samples retrieved from
the files of Pathology Division of Barretos Cancer Hos-
pital, São Paulo, Brazil, which included 28 cases of chronic
cervicitis, 34 cases of cervical intraepithelial neoplasia
grade I (CIN 1, herein designated as low-grade squa-
mous intraepithelial lesion - LSIL), 29 cases of cervical
intraepithelial neoplasia grades II and III (CIN2/3, here-
in designated as high-grade squamous intraepithelial le-
sions - HSIL) and 38 cases of squamous cells carcinoma
(SCC) of the uterine cervix. SCC samples were organized
into one tissue microarray (TMA), with 96 tumour cores
(one mm diameter), also including several control samples
(kidney and placenta). Each case was represented in the
TMA by at least two cores. Clinicopathological data of the
patients included age at diagnosis, tumour size, histo-
logical grade, clinical stage, vascular invasion, lymph-node
and distant metastasis, recurrence and survival; how-
ever, since histological grade, vascular invasion, lymph-
node and distant metastasis, recurrence and survival were
poorly represented in one of the groups, only age at diag-
nosis (mean 48 years), tumour size (mean 2 cm) and FIGO
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IIB case, grouped in clinical stage I and clinical stage II)
were used for statistical analysis.
The ethics committee of Barretos Cancer Hospital ap-
proved this study. As retrospective study, the Ethical
Committee does not require the written informed consent
from the patients. The patients previously supplied con-
sent for the samples to be used for research purposes.
Epithelial raft cultures
Low passage-pooled neonatal foreskin keratinocytes
(Lonza Walkersville, Inc., Walkersville, MD) were grown
in keratinocyte serum-free medium (Invitrogen, Frederick,
MD). Cells were acutely infected with recombinant
pLXSN retrovirus vectors either empty or containing
HPV16 E6, E7 or both E6/E7, and expressing the neomy-
cin resistance marker. After 24 hours, the cells were se-
lected with 250 μg/ml of G418 for two days, when 100%
of mocked infected controls were dead. Recombinant
pLXSN retrovirus vectors were kindly provided by Dr.
Denise Galloway (Fred Hutchinson Cancer Research
Center, Seattle, WA) and are described elsewhere [22].
The cell lines FK16A and FK18B were established by
transfection of primary human foreskin keratinocytes (FK)
with the entire HPV16 and HPV18 genome and cultured
for different passage number as previously described [23].
All cells were used to seed epithelial rafts cultures, as pre-
viously described [23].
Immunohistochemistry
MCT1 and CD147 immunohistochemistry was performed
according to the avidin-biotin-peroxidase complex me-
thod (R.T.U. VECTASTAIN Elite ABC Kit (Universal),
Vector Laboratories, Burlingame, CA), as previously
described [24]. Immunohistochemistry for MCT2,
MCT4, GLUT1 and CAIX was performed according
to the streptavidin-biotin-peroxidase complex principle
(Ultravision Detection System Anti-polyvalent, HRP, Lab
Vision Corporation, Fremont, CA), as previously de-
scribed [25,26]. Negative controls were performed by the
use of appropriate serum controls for the primary anti-
bodies (N1698 and N1699, Dako, Carpinteria, CA). Colon
carcinoma tissue was used as positive control for MCT1,
and MCT4 and CD147, kidney was used for MCT2, head
and neck cancer was used for GLUT1 and stomach was
used for CAIX. Tissue sections were counterstained with
hematoxylin and permanently mounted. Please refer to
Table 1 for detailed aspects for each antibody used.
For VEGFs immunohistochemical analyses, the immu-
nohistochemical staining was performed automatically
with Ventana Benchmark® XT (Ventana Medical Sys-
tems, Tucson, AZ) following the manufacturer’s guide-
lines and then counterstained with hematoxylin and
permanently mounted. Negative controls were obtainedby omitting the primary antibody incubation step and
human tonsils were used as positive control. Please refer
to Table 1 for detailed aspects for each antibody used.
Immunohistochemical evaluation
Sections were scored semi-quantitatively for plasma
membrane expression (metabolic markers) and cyto-
plasmic expression (vascular markers) in cancer cells as
follows: 0: 0% of immunoreactive cells; 1: <5% of immu-
noreactive cells; 2: 5-50% of immunoreactive cells; and
3: >50% of immunoreactive cells. Also, intensity of stai-
ning was scored semi-qualitatively as follows: 0: nega-
tive; 1: weak; 2: intermediate; and 3: strong. The final
score was defined as the sum of both parameters (ex-
tent and intensity), and grouped as negative (score 0
and 2) and positive (score 3–6), as previously described
[24]. Protein expression in other cellular localizations
was also assessed. Two independent observers (AL-F
and EAG) performed immunohistochemical evaluation
blindly and discordant results were discussed in a
double-head microscope in order to determine the final
score.
Statistical analysis
Data were stored and analysed using the IBM SPSS Sta-
tistics software (version 20, IBM Company, Armonk,
NY). All comparisons were examined for statistical sig-
nificance using Pearson’s chi-square (χ2) test and Fisher’s
exact test (when n < 5). The threshold for significant p
values was established as p < 0.05.
Results
Human samples
The immunohistochemical evaluation showed that all
the metabolic markers can be expressed in the cyto-
plasm, in the plasma membrane or exhibit both localiza-
tions. Figure 1 shows microphotographies representative
of the expression of each protein, in each lesion. Import-
antly, only plasma membrane expression was considered
for statistical analysis, as plasma membrane is required
for the activity of the proteins studied as plasma mem-
brane transporters or pH regulators.
Table 2 summarizes the expression frequencies at the
plasma membrane of the metabolic markers MCT1,
MCT4, CD147, GLUT1 and CAIX in cervicitis and from
low-grade lesions towards SCC. MCT1 showed a gradual
increase in its expression frequency along progression,
however, without statistical significance. In opposition,
the increase of MCT4 frequency was significantly higher
in SCC, when compared with cervicitis, LSIL and HSIL
(p = 0.005). CD147 followed a pattern of expression simi-
lar to MCT1, also without statistical significance, while
GLUT1 was significantly increased in malignant lesions
when compared with non-malignant lesions (p = 0.025).
Table 1 Detailed aspects for each antibody used in immunohistochemistry
Protein Antigen retrieval Antibody Antibody dilution and incubation time
MCT1 Citrate buffer (0.01 M, pH = 6), 98°C, 20’ AB3538P 1:200, overnight
Chemicon International
MCT2 Citrate buffer (0.01 M, pH = 6), 98°C, 20’ sc-50322 1:200, 2 hours
Santa Cruz Biotechnology
MCT4 Citrate buffer (0.01 M, pH = 6), 98°C, 20’ sc-50329 1:500, 2 hours
Santa Cruz Biotechnology
CD147 EDTA (1 mM, pH = 8), 98°C, 20’ sc-71038 1:400, overnight
Santa Cruz Biotechnology
GLUT1 Citrate buffer (0.01 M, pH = 6), 98°C, 20’ ab15309-500 1:500, 2 hours
AbCam
CAIX Citrate buffer (0.01 M, pH = 6), 98°C, 20’ ab15086 1:2000, 2 hours
AbCam
VEGF-A CC1 (pH = 8,2) Ventana VG-1 1:200, 60 minutes
AbCam
VEGF-C ptLink (pH = 9) Dako 18-2255 1:200, 60 minutes
Invitrogen
VEGF-D ptLink (pH = 9) Dako ab63068 1:50, 60 minutes
AbCam
VEGFR-1 ptLink (pH = 9) Dako ab9540 1:300, 60 minutes
AbCam
VEGFR-2 ptLink (pH = 9) Dako ab2349 1:100, 60 minutes
AbCam
VEGFR-3 ptLink (pH = 9) Dako ab72240 1:50, 60 minutes
AbCam
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groups (p = 0.004), but with no gradual increase/decrease
along progression to malignancy.
The co-expression between the different markers was
also analysed. Considering all the human uterine cervix
samples, MCT4 was significantly co-expressed with both
CD147 and CAIX (p = 0.030 and p = 0.014, respectively),
but not with GLUT1, while MCT1 was not significantly
co-expressed with none of these three proteins (data not
shown). Concerning the VEGF family members, over-
all, these proteins, with the exception of VEGFR-1 and
VEGFR-2, presented a high intensity and extension of ex-
pression (Figure 2). No significant co-expression was ob-
served between the expression of the ligands and the
receptors (data not shown). When evaluating the possible
co-expression between the metabolic and the vascular
markers, a significant association between absence of
MCT1 and presence of VEGF-A was found (Table 3, p =
0.013). To note, VEGF-D was not included in the latter
analysis, as only 1 case was negative.
Results from the analysis of the expression of the dif-
ferent proteins and the available clinicopathological data
of SCC is shown in Table 4. The only associations foundwere between both MCT4 and CD147 and patients youn-
ger at diagnosis (p = 0.029 and p = 0.024, respectively).
Additional statistical analysis was performed (data not
shown), assembling groups with different patterns of ex-
pression, by combining positivity for more than one pro-
tein (for example, co-expression of MCT1 with CD147
and VEGF-A). Importantly, co-expression of MCT1 with
GLUT1 and CAIX was significantly associated with clin-
ical stage, as stage I presented three (10.7%) positive cases
and stage II three (60.0%) positive cases (p = 0.031).
Epithelial organotypic rafts cultures
Immunohistochemical expression analysis of the different
key metabolic proteins was also performed using epithelial
organotypic rafts cultures obtained from low passage kera-
tinocytes expressing HPV16 E6 and/or E7 expression, as
well as from PHK transfected with HPV16 or 18 full-
length genomes and grown during different passages be-
fore raft culture seeding (Figures 3 and 4). Expression of
HPV oncoproteins did not influence MCT1 expression;
however, E7 expression upregulates MCT4 in the basal
layer of the epithelium and increases the expression of
CD147 throughout the epithelium thickness. Importantly,
Figure 1 Immunohistochemical expression of MCT1, MCT4, CD147, GLUT1 and CAIX in cervical samples. All the proteins were more
importantly found in the plasma membrane of cells.
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which resemble severe dysplasia in vivo, present an in-
crease in MCT4 expression and the same was observed
for CD147 in HPV16 and 18-transfected cells, with no ap-
parent change in MCT1 expression. Concerning GLUT1,
neither E6 nor E7 seem to affect its expression, while high
passage after HPV16 transfection seems to stimulate
GLUT1 expression. Finally, CAIX seems to be increased
after E6 and/or E7 expression, while passage number in
HPV16-transfected cells also increased the expression in-
tensity of this protein.Table 2 Frequency of expression of the metabolic markers alo
MCT1 MCT4
n Positive (%) p n Positive (%) P n Pos
0.252 0.005
Cervicitis 28 6 (21.4) 27 6 (22.2) 24
LSIL 33 9 (27.3) 30 8 (26.7) 34
HSIL 28 9 (32.1) 28 6 (21.4) 29
SCC 34 15 (44.1) 33 19 (57.6) 32 6
Note: the number of lesion samples analysed for each marker varies due to loss of
the sample.Discussion
Recently, the cancer metabolic adaptations have been in-
cluded in the well-known Hallmarks of Cancer [27].
Aerobic glycolysis, although being a much less efficient
energetic pathway than mitochondrial oxidative phospho-
rylation, is a successful adaptation to hypoxic microen-
vironment, allows cancer cells to use the most abundant
extracellular nutrient, glucose, to produce ATP, and excess
pyruvate provides a source for anabolic substrates essen-
tial for biosynthetic pathways [28]. Hypoxia conditions,
which are known to induce the glycolytic phenotype, areng progression to malignancy in cervical samples
CD147 GLUT1 CAIX
itive (%) p n Positive (%) p n Positive (%) p
0.071 0.025 0.004
0 (0.0) 24 12 (50.0) 26 11 (42.3)
2 (5.9) 34 29 (85.3) 34 4 (11.8)
2 (6.9) 29 19 (65.5) 29 8 (27.6)
(18.8) 37 28 (75.7) 33 17 (51.5)
material during IHC procedure or lack of representativity of the lesion in
Figure 2 Immunohistochemical expression of VEGF family in SCC samples. (A) VEGF-A; (B) VEGF-C; (C) VEGF-D; (D) VEGFR-1; (E) VEGFR-2;
and (F) VEGFR-3.
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evidence points at hypoxia-mediated increase of MCT4,
but not MCT1 [29], while other points at regulation of
both MCT isoforms by hypoxia [30]. This controversial
data on MCT regulation by hypoxia, especially MCT1,Table 3 Association between the metabolic markers and the
VEGF-A VEGF-C
n Positive (%) p n Positive (%) p n Po
MCT1 0.013 1.000
Negative 17 16 (94.1) 19 18 (94.7) 19
Positive 15 8 (53.3) 15 14 (93.3) 15
MCT4 0.108 0.172
Negative 12 11 (91.7) 14 12 (85.7) 14
Positive 19 12 (63.2) 19 19 (100.0) 19
CD147 0.645 1.000
Negative 24 18 (75.0) 26 25 (96.2) 26
Positive 6 4 (66.7) 6 6 (100.0) 6
GLUT1 0.390 0.553
Negative 8 7 (87.5) 9 9 (100.0) 9
Positive 27 18 (66.7) 26 23 (88.5) 26
CAIX 0.685 0.485
Negative 15 12 (80.0) 16 16 (100.0) 16
Positive 16 11 (68.8) 17 15 (88.2) 17instigated us to further investigate this association be-
tween MCTs and hypoxia, by analysing the co-expression
of these proteins with GLUT1 and CAIX, which are tar-
gets of HIF-1α [8,9]. It is important to mention, however,
that, as described in few studies, both HIF-1α and GLUT1vascular markers in SCC samples
VEGFR-1 VEGFR-2 VEGFR-3
sitive (%) p n Positive (%) p n Positive (%) p
0.370 0.426 0.722
2 (10.5) 19 14 (73.7) 18 6 (33.3)
4 (26.7) 15 13 (86.7) 15 4 (26.7)
0.209 0.670 1.000
1 (7.1) 14 12 (85.7) 14 4 (28.6)
5 (26.3) 19 14 (73.7) 19 6 (31.6)
1.000 1.000 0.314
5 (19.2) 26 20 (76.9) 26 6 (23.1)
1 (16.7) 6 5 (83.3) 6 3 (50.0)
0.340 1.000 0.205
3 (33.3) 9 7 (77.8) 8 4 (50.0)
4 (15.4) 26 21 (80.8) 25 6 (24.0)
0.175 0.398 0.909
1 (6.2) 16 14 (87.5) 16 5 (31.2)
5 (29.4) 17 12 (70.6) 17 5 (29.4)
Table 4 Association of the metabolic and vascular markers expression with the clinicopathological variables in SCC
samples
MCT1 MCT4 CD147 GLUT1 CAIX
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Age* 0.901 0.029 0.024 0.711 0.208
> 48 14 6 (42.9) 14 5 (35.7) 14 0 (0.0) 15 12 (80.0) 14 9 (64.3)
≤ 48 20 9 (45.0) 19 14 (73.7) 18 6 (33.3) 22 16 (72.7) 19 8 (42.1)
Tumour size* 0.644 0.600 1.000 0.624 1.000
≤ 2 cm 11 4 (36.4) 11 7 (63.6) 11 2 (18.2) 14 10 (71.4) 11 4 (36.4)
> 2 cm 6 3 (50.0) 6 5 (83.3) 6 1 (16.7) 7 6 (85.7) 6 2 (33.3)
Clinical stage 0.634 0.138 1.000 0.307 0.335
I 29 12 (41.4) 28 18 (64.3) 27 5 (18.5) 32 23 (71.9) 28 13 (46.4)
II 5 3 (60.0) 5 1 (20.0) 5 1 (20.0) 5 5 (100.0) 5 4 (80.0)
VEGF-A VEGF-C VEGFR-1 VEGFR-2 VEGFR-3
n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p n Positive (%) p
Age* 0.270 1.000 0.681 1.000 0.455
> 48 13 11 (84.6) 14 13 (92.9) 14 2 (14.3) 14 11 (78.6) 14 3 (21.4)
≤ 48 23 15 (64.2) 22 20 (90.9) 22 5 (22.7) 22 18 (81.8) 19 7 (36.8)
Tumour size* 0.624 1.000 0.517 0.557 0.600
≤ 2 cm 14 10 (71.4) 13 12 (92.3) 13 3 (23.1) 13 11 (84.6) 11 4 (36.4)
> 2 cm 7 6 (85.7) 6 6 (100.0) 6 0 (0.0) 6 4 (66.7) 6 1 (16.7)
Clinical stage 0.603 0.370 0.559 0.244 0.627
I 31 23 (74.2) 31 29 (93.5) 31 7 (22.6) 31 26 (83.9) 28 8 (28.6)
II 5 3 (60.0) 5 4 (80.0) 5 0 (0.0) 5 3 (60.0) 5 2 (40.0)
*Mean values were used for age and tumour size cut-off.
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in cervical cancer [31,32].
Firstly, the pattern of expression of these markers was
analysed concerning the progression from cervicitis,
through LSIL, HSIL and finally SCC. In accordance to
the previous publication from our group using a different
cervical cancer series [33,34], both MCT1 and MCT4
showed an increased expression towards malignancy, al-
though only significant for MCT4. Importantly, in this
study, the tendency for an increase in plasma membrane
expression of MCT1 and CD147 was more evident than
in the previous studies. Unfortunately, due to the low
number of cases these increases were not significant but
the predominant membranous pattern of concomitant
immunoreaction of both markers suggest a potential
more effective metabolic activity, which can play a role in
cancer development. GLUT1 expression, although with
significantly different frequencies of expression among the
lesions, did not follow a gradual increase towards malig-
nancy. Previous results from others have described a pro-
gressive increase of GLUT1 from normal cervical tissue,
to precursor lesions and SCC [35,36]. CAIX showed a
gradual expression frequency in cervical lesions, according
to lesion grade. Notably, its expression in cervicitis wasalmost as frequent as in SCC. This observation may be
explained by the association between hypoxia and inflam-
mation, as pro-inflammatory cytokines like TNF-α can
stimulate HIF-1α activity [37] and, as a consequence, in-
duce CAIX expression. Therefore, ideally, normal cervical
samples instead of cervicitis samples should be used, how-
ever, these samples are difficult to obtain as biopsies are
only performed when there is suspicion of lesion.
When comparing the expression of MCT1 with its
chaperone CD147 and the hypoxia-induced GLUT1 and
CAIX, no significant associations were found. However,
for CD147, this lack of association may be associated
with the low number of cases. Additionally, as hypothe-
sised in other studies [33,38-40], other chaperones not
yet identified should be involved in MCT trafficking to
the plasma membrane. In opposition, we found a signifi-
cant co-expression between MCT4 and both CD147 and
CAIX, and a tendency for co-expression with GLUT1.
These results go along with the hypothesis that MCT4,
but not MCT1, is associated with hypoxia [29] and also
with the hyper-glycolytic (GLUT1) and acid-resistant phe-
notype (CAIX) of cancer cells. Therefore, MCT4 would
be important for the efflux of lactate and protons in
hyper-glycolytic cancer cells, allowing maintenance of
Figure 3 Expression of metabolic proteins after transduction with HPV16 oncogenes. The expression of MCT1, MCT4, CD147, GLUT1 and
CAIX was evaluated by immunohistochemistry in in vitro 3D cultures of keratinocytes transduced with HPV16 oncogenes.
Figure 4 Expression of metabolic proteins after transfection with HPV16 or HPV18 full genome. The expression of MCT1, MCT4, CD147,
GLUT1 and CAIX was evaluated by immunohistochemistry in in vitro 3D cultures of keratinocytes transfected with HPV16 or HPV18 full genome.
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apoptosis resultant from low intracellular pH.
Overall, the results obtained with the human samples
were confirmed in vitro, with the 3D culture of keratino-
cytes expressing HPV genes. At the best of our know-
ledge, this is the first study that attempted to evaluate
metabolic markers in epithelial rafts expressing E6 and
E7 HPV oncogenes. In the literature, studies by others
show contradictory results about the possible effect of
HPV infection in the metabolic behaviour of cancer
cells. In one hand, HPV infection has been demons-
trated to stabilize HIF-1α expression [41,42]. As HIF-1α
is the major regulator of the Warburg effect [7], one
could conclude that HPV infection will stimulate gly-
colysis enhancing the expression of glycolytic-associated
proteins. However, in the other hand, it was described
that HPV16 E7 oncoprotein expression stimulates gluta-
minolysis, decreasing glucose consumption and lactate
production [43]. In the present study, we found that
both MCT4 and CD147 were stimulated in E7 expres-
sing cells, while CAIX was stimulated by E6 and E7,
alone or in combination, which is in accordance with
the stimulation of the Warburg effect, as a result of
HPV-dependent HIF-1α stabilization [41,42]. However,
both MCT1 and GLUT1 were not affected by E6 and/or
E7 expression, which, for MCT1, once again, suggest
that this protein may not be induced by HIF-1α, at least
in this model. Besides, for GLUT1, this observation is in
accordance with the results from the human samples as
well as the previous results showing the stimulation of
glutaminolysis, but not glycolysis, after HPV16 E7 onco-
protein expression [43]. This stimulation of glutaminolysis
would also explain MCT4 increase, as glutaminolysis also
leads to lactate production. Additionally, high passage
HPV16 whole genome transfected cells present higher ex-
pression of MCT4, CD147, GLUT1 and CAIX, while
HPV18 whole genome transfected cells present higher ex-
pression of CD147. As organotypic cultures obtained from
HPV-positive cells at low passage number (FK16A p19
and FK18B p27) exhibit morphological alterations remi-
niscent of mild/moderate dysplasia while those obtained
from the same cells at high passage number (p > 80) ex-
hibit more severe dysplastic features, we can hypothesise
that MCT4, CD147, GLUT1 and CAIX are increased dur-
ing HPV-associated lesion.
It is well-known that tumour acidity facilitates cancer
cell invasion behaviour [44]. Additionally, cancer acid-
osis is also associated with mutagenesis/clastogenesis,
radioresistance and resistance to anthracyclines [2]. Al-
though sharing its role as tumour acidifier with other
sources of acidity like carbon dioxide, lactate has been
proven to cause acidification of tumour microenviron-
ment [45]. Importantly, lactate has other properties which
contribute modestly to the malignant behaviour of cancercells; exogenous lactate was demonstrated to increase cel-
lular motility [46], induce VEGF [20], as well as hyaluro-
nan and its receptor CD44, which are molecules involved
in the process of cancer invasion and metastisation [47].
As a result, lactate can enhance the malignant phenotype
of tumour cells, contributing to the association of high
tumour lactate concentrations with incidence of metasta-
ses, tumour recurrence, patient survival [48] and radiore-
sistance [49]. Following this rationale, we analysed the
expression of vascular factors in the SCC samples and ver-
ify its co-expression with the metabolic markers. Firstly,
we observed an overall high expression of the members of
the VEGF family, especially the ligands. This is in accord-
ance with previous publications from other authors, where
high expression of VEGF family members is described
in cervical cancer [50]. As a result of this high ex-
pression, as well as the low number of cases, no sig-
nificant associations were found when analysing the
possible co-expression of VEGF ligands with the receptors.
Interestingly, when analysing the co-expression of the
metabolic markers with the vascular markers, we found an
inverse association between MCT1 and VEGF-A. As de-
scribed for colorectal cancer with MCT4 and VEGF-A
[51], it is possible that these proteins are involved in differ-
ent stages of tumour progression, where VEGF-A is in-
volved in the early stages of tumour growth while MCTs,
in this case MCT1, appears as the tumour enlarges and
may contribute to further tumour infiltration and growth.
Our data on association with tumour size do not support
this hypothesis, however, the number of cases with infor-
mation on tumour size is even lower, with only 21 cases
available for analysis, losing statistical power. Further stud-
ies, with a higher number of samples, are required to val-
idate this inverse association and additional experiments
are needed to elucidate the molecular mechanisms, if any,
behind this event.
The clinicopathological significance of the metabolic
markers analysed in the present study has been previously
evaluated by us and others [33-36,52-55]. Although we
were not able to found any associations with the clinico-
pathological data of SCC in our previous studies with
MCTs and CD147 [33,34], other studies have found asso-
ciation of CD147, GLUT1 and CAIX expression with
lymph-node metastasis [35,52,54], while CAIX was also
associated with advanced tumour stage, greater invasion
depth, undifferentiated tumour grade [52], as well as dis-
tant metastasis in early-stage cervical cancer [53]. Also,
absence of GLUT1 was shown to significantly increase the
likelihood of metastasis-free survival in locally advanced
cervical carcinoma but not of disease-free or recurrence-
free survival [55]. However, another study showed that,
despite the increased expression of HIF-1α, GLUT1 and
CAIX in cervical cancer, only HIF-1α was associated with
poor prognostic variables like lymph node metastasis and
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nificant association of both MCT4 and CD147 with youn-
ger patients at time of diagnosis. Cervical cancer is a
cancer of late onset, as tumours take years to develop
since high-risk HPV type infection, which is a necessary
cause for the development of these tumours [56]. There-
fore, we hypothesize that MCT4 and CD147 expression
may provide to the abnormal cells a survival advantage
and a potential for progression that allow tumours to arise
earlier. Additionally, we also found significant associ-
ation between co-expression of MCT1/GLUT1/CAIX
and higher clinical stage, which is in accordance with
the more aggressive behaviour of hyper-glycolytic and
acid-resistant cancer cells. In respect to VEGF family
members, although some studies show the clinicopatho-
logical value of VEGF family members in cervical cancer
[50,57,58], in the present study, we found no association
of VEGFR family members and the clinicopathological
variables available, which, at least for VEGF-A, is in ac-
cordance with another previous study [59]. Further stud-
ies, with larger and best characterized squamous cervical
cancer series, are required to rigorously confirm these
results, as well as evaluate possible associations with
survival.
Conclusions
In the present study, we confirmed the induction of
MCT4 in the progression towards malignancy in cervical
squamous cells carcinoma, pointing at this protein as a
promising therapeutic target. This increase seems to be
associated with hypoxia or HPV-induced HIF-1α sta-
bilization and is accompanied by CD147 and CAIX, but
not GLUT1, expression. With this evidence, we take a
small step forward regarding MCT behaviour in res-
ponse to hypoxic conditions/HIF-1α, providing additio-
nal evidence for the regulation of MCT4, but not MCT1,
under these conditions. Also, we show an inverse associ-
ation between MCT1 and the major angiogenic factor
VEGF-A, which should be further explored in a larger cer-
vical cancer series, including also other histological types
like adenocarcinomas, as well as in series from other
tumours types.
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